The purpose of this study is to quantify the magnitude and extent of infant exposure to daily
emtricitabine (FTC) /tenofovir disoproxil fumarate (TDF) via maternal breastmilk when taken
pre-exposure prophylaxis (PrEP) by lactating HIV-uninfected women. The primary outcome is the
steady state concentrations of emtricitabine and tenofovir in the infant plasma.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Washington
Collaborator:
Bill and Melinda Gates Foundation
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir